HIV_1蛋白酶抑制剂前药地研究进展.pdfVIP

2005 年第2 卷 第7 期 第 295 页 # # 药学进展 Progress in Pharmaceutical Sciences 2005, Vol . 29, No. 7 295 cytidine nucleoside analog with activity against zidovudine- Chemother, 1 0, 34(6) : 1061-10671 and lamivudine-resistant viral variants[J] . Antimicrob Agents [ 14] De Clercq E. Antiviral drugs: current state of the art[J] . J Chemother, 2002, 46 (5) : 13 4- 14011 Clin Virol, 2001, 22 ( 1) : 73-8 1 [ 10] Stuyver L J, McBrayer T R, Sch™rmann D, et al. Potent an- [ 15] De Clercq E. New anti-HIV agents in preclinical or clinical tiviral effect of Reverset TM in HIV- 1 infected adults following development[ J] . Front Med Chem, 2004, 37 ( 1) : 543- a single oral dose[ J] . A ntiviral Ther, 2004, (4) : 52 - 57 1 5361 [ 16] , , , . [J] . 有机化 [ 11] Dunkle L M, Gathe J C, Pedevillano D E, et al. Elvu- 学, 2003, 23( 10) : 10 1- 10 81 citabine: potent antiviral activity demonstrated in mult-i drug [ 17] Zemlicka J. Enantioselectivity of the antiviral effects of nucle- resistant HIV infection[J] . Antiviral Ther, 2003, 8: S51 oside analogues [J] . Pharmacol Ther, 2000, 85(3) : 251- [ 12] Bogner J R, Roecken M, Herrmann D B, et al. Phase Ñ/ 2661 Ò trial with fozivudine tidoxil ( BM 21. 12 0) : a 7 day ran- [ 18] , , , . domized, placebo-controlled dose-escalating trial[ J] . A ntivi- [J] . 化学研究与应用, 2002, 14( 1) : 15-201 ral Ther, 1 7, 2(4) : 257-2641 [ 1 ] Ballatore C, McGuigan C, De C1ercq E, et al. Synthesis [ 13] Schinazi R F, Sommadossi J P, Saalmann V, et al. Activities and evaluation of novel amidate prodrug of PMEA and PMPA of 3.-azido-3.-deoxythymidine nucleotide dimers in primary [J] . Bioorg Med Chem